NovoCure Limited
NovoCure Limited (NVCR) Financial Performance & Income Statement Overview
Review NovoCure Limited (NVCR) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
NovoCure Limited (NVCR) Income Statement & Financial Overview
View the income breakdown for NovoCure Limited NVCR across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $154.99M | $161.27M | $155.09M | $150.36M |
| Cost of Revenue | $38.52M | $33.47M | $35.37M | $34.65M |
| Gross Profit | $116.47M | $127.80M | $119.72M | $115.70M |
| Gross Profit Ratio | $0.75 | $0.79 | $0.77 | $0.77 |
| R&D Expenses | $53.78M | $51.21M | $51.88M | $54.95M |
| SG&A Expenses | $100.56M | $139.89M | $99.93M | $94.35M |
| Operating Expenses | $154.34M | $191.10M | $151.81M | $149.31M |
| Total Costs & Expenses | $192.86M | $224.57M | $187.19M | $183.96M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.33M | $3.10M | $2.46M | $2.86M |
| EBITDA | -$34.54M | -$10.52M | -$29.63M | -$30.75M |
| EBITDA Ratio | -$0.22 | -$0.07 | -$0.19 | -$0.20 |
| Operating Income | -$37.87M | -$63.30M | -$32.09M | -$33.61M |
| Operating Income Ratio | -$0.24 | -$0.39 | -$0.21 | -$0.22 |
| Other Income/Expenses (Net) | $7.57M | $8.10M | $10.51M | $10.85M |
| Income Before Tax | -$30.30M | -$55.21M | -$21.59M | -$22.73M |
| Income Before Tax Ratio | -$0.20 | -$0.34 | -$0.14 | -$0.15 |
| Income Tax Expense | $4.02M | $10.72M | $8.98M | $10.65M |
| Net Income | -$34.32M | -$65.92M | -$30.57M | -$33.38M |
| Net Income Ratio | -$0.22 | -$0.41 | -$0.20 | -$0.22 |
| EPS | -$0.31 | -$0.61 | -$0.28 | -$0.31 |
| Diluted EPS | -$0.31 | -$0.61 | -$0.28 | -$0.31 |
| Weighted Avg Shares Outstanding | $110.28M | $107.83M | $108.25M | $107.70M |
| Weighted Avg Shares Outstanding (Diluted) | $110.28M | $107.83M | $108.25M | $107.70M |
The company's financials show resilient growth, with revenue advancing from $150.36M in Q2 2024 to $154.99M in Q1 2025. Gross profit remained healthy with margins at 75% in Q1 2025 compared to 77% in Q2 2024. Operating income hit -$37.87M last quarter, sustaining a consistent -24% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$34.54M. Net income rose to -$34.32M, while earnings per share reached -$0.31. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan